Boston Scientific today announced FDA approval of its Agent drug-coated balloon (DCB), making it the first coronary DCB indicated for in-stent restenosis (ISR) in patients with coronary artery disease ...

A paclitaxel-coated device, Agent, has become the first coronary DCB in the United States to be approved for the treatment of in-stent restenosis (ISR), Boston Scientific announced today. The Food and ...

WASHINGTON, DC—-Results from the full cohort of patients treated with a newly approved DCB for in-stent restenosis confirm its superiority over an uncoated balloon, and investigators say it will ...

Data from first coronary DCB study in U.S. meet 12-month primary endpoint, demonstrate low adverse event rates with AGENT DCB While coronary stenting is commonly used to restore blood flow to the ...

SAN FRANCISCO -- The Agent paclitaxel-coated balloon was better than conventional balloon angioplasty for in-stent restenosis (ISR), according to the AGENT IDE pivotal trial that will be used to ...

The US Food and Drug Administration (FDA) has approved Boston Scientific's Agent Drug-Coated Balloon (DCB), the first coronary DCB for the treatment of coronary in-stent restenosis in patients with ...

Boston Scientific Corporation BSX achieved a milestone with the recent FDA approval for its AGENT Drug-Coated Balloon (DCB). This marks the first drug-coated coronary balloon available in the United ...

First coronary drug-coated balloon in U.S. provides safe, effective alternative to treat coronary in-stent restenosis and reduce risk of reoccurrence MARLBOROUGH, Mass., March 1, 2024 /PRNewswire/ -- ...

Global medical device maker Boston Scientific recently reported that it had received CE (Conformité Européenne) approval for its Agent drug-coated balloon catheter for the coronary market. The Agent ...

San Francisco — For the treatment of coronary artery in-stent restenosis, angioplasty with a drug-coated balloon (AGENT DCB; Boston Scientific) was superior to conventional balloon angioplasty in ...

Please provide your email address to receive an email when new articles are posted on . A novel coronary drug-coated balloon using a reduced dose of paclitaxel was noninferior at 1 year to a ...